Novavax Inc. Stock
€6.35
Your prediction
Novavax Inc. Stock
Pros and Cons of Novavax Inc. in the next few years
Pros
Cons
Performance of Novavax Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novavax Inc. | -0.490% | -2.087% | 12.458% | -61.830% | -18.938% | -84.723% | -83.788% |
| Krystal Biotech | 1.600% | 2.627% | -21.519% | -23.498% | -24.277% | 125.980% | - |
| Ardelyx Inc. | 1.160% | -1.371% | -5.399% | -45.672% | -30.473% | 451.614% | -47.298% |
| Evolus Inc | -1.180% | -0.585% | -18.269% | -26.087% | -19.048% | -34.615% | 94.064% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.General Impression
The financials of Novavax, a Biotechnology & Medical Research company with US symbol NVAX, paint a mixed picture. Over the past few years, the company has reported a significant increase in its revenue and total assets. However, its net income has consistently been in the negative, and it has faced challenges in maintaining a positive net working capital and managing its liabilities.
Detailed Analysis
Comments
News
Novavax Stock: FDA Approval Triggers Financial Windfall
The U.S. Food and Drug Administration has granted full approval (Biologics License Application) for Novavax's COVID-19 vaccine Nuvaxovid, marking a significant breakthrough for the biotech company
2 Beaten-Down Stocks That Still Aren't Worth Buying
President Trump's trade policies are sending many stocks that were performing well in the wrong direction and exacerbating things for others that were already struggling. So, the time seems ripe for
2 Beaten-Down Stocks Near Their 52-Week Lows That Aren't Worth Buying
Buying stocks after they have lost significant market value can lead to excellent returns in the long run, but only if the company in question can reverse its fortunes.
Sometimes, corporations lag